癸酸雌二醇

癸酸雌二醇
临床资料
其他名称	E2D、17β-癸酸雌二醇、雌二醇癸酸酯、17β-癸酸雌-1,3,5(10)-三烯-3,17β-二醇
给药途径	口服
药物类别（英语：Drug class）	雌激素; 雌激素酯
识别信息
	IUPAC命名法 [(8R,9S,13S,14S,17S)-3-Hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] decanoate; ;
CAS号	61748-93-4
PubChem CID	66409;
ChemSpider	59783;
UNII	S4J8Z2L5LZ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID90210752 ;
化学信息
化学式	C28H42O3
摩尔质量	426.64 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES CCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C;
	InChI InChI=1S/C28H42O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h12,14,19,23-26,29H,3-11,13,15-18H2,1-2H3/t23-,24-,25+,26+,28+/m1/s1; Key:YYFQNZXJGOTFRX-VMBLQBCYSA-N;

癸酸雌二醇（英语：Estradiol decanoate，简称E2D）或叫雌二醇癸酸酯或17β-癸酸雌二醇，是一种合成的甾体雌激素和雌激素酯，在1970年代后期被研究用于切除卵巢的女性的激素替代疗法，但从未上市销售。^[1]^[2]^[3]

Quick Facts 临床资料, 其他名称 ...

Close

已经在切除卵巢的妇女中研究了以0.25至0.5毫克/天的剂量口服油中的癸酸雌二醇，持续14天，发现产生的雌酮和雌二醇水平约为1:2 (0.5)至1:1.7 (0.6)。^[1]^[2]这与口服微粉化雌二醇相反，后者的雌酮与雌二醇之比约为5:1（与口服油中的癸酸雌二醇相比，比例相差8至10倍）。^[4]女性雌酮与雌二醇的正常比例在绝经前女性中约为1:2 (0.5)，在绝经后女性中约为2:1。^[4]因此，与口服微粉化雌二醇相比，口服油中的雌二醇癸酸酯可以提供更生理和更有利的雌酮和雌二醇水平。^[1]^[2]

口服癸酸雌二醇油中雌酮与雌二醇比率的优化可能与通过肠道淋巴系统的吸收有关，这使其可绕过肝脏中的首过代谢。^[5]这取决于癸酸雌二醇的脂肪酸癸酸酯，因此，不溶于油的口服癸酸雌二醇对啮齿动物的影响较小或没有。^[5]通过淋巴系统吸收油中的口服雌二醇癸酸酯类似于油中的口服十一酸睾酮的情况。^[6]

参见

雌激素酯列表

参考资料

[1]
Kicovic PM, Luisi M, Franchi F, Alicicco E. Effects of orally administered oestradiol decanoate on plasma oestradiol, oestrone and gonadotrophin levels, vaginal cytology, cervical mucus and endometrium in ovariectomized women. Clin. Endocrinol. (Oxf). July 1977, 7 (1): 73–7. PMID 880735. S2CID 13639429. doi:10.1111/j.1365-2265.1977.tb02941.x.
[2]
Luisi M, Kicovic PM, Alicicco E, Franchi F. Effects of estradiol decanoate in ovariectomized women. J. Endocrinol. Invest. 1978, 1 (2): 101–6. PMID 755846. S2CID 38187367. doi:10.1007/BF03350355.
[3]
Ranjit Roy Chaudhury. Pharmacology of Estrogens. Elsevier Science & Technology Books. 1 January 1981: 36. ISBN 978-0-08-026869-9.
[4]
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2023-02-16]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始内容存档 (PDF)于2016-08-22）.
[5]
de Visser J, van der Vies J. Oestrogenic activity of oestradiol-decanoate after oral administration to rodents. Acta Endocrinol. June 1977, 85 (2): 422–8. PMID 577331. doi:10.1530/acta.0.0850422.
[6]
Alexandre Hohl. Testosterone: From Basic to Clinical Aspects. Springer. 30 March 2017: 207–. ISBN 978-3-319-46086-4.

这是一篇关于类固醇的小作品。您可以通过编辑或修订扩充其内容。

[pmid880735-1] [1]
Kicovic PM, Luisi M, Franchi F, Alicicco E. Effects of orally administered oestradiol decanoate on plasma oestradiol, oestrone and gonadotrophin levels, vaginal cytology, cervical mucus and endometrium in ovariectomized women. Clin. Endocrinol. (Oxf). July 1977, 7 (1): 73–7. PMID 880735. S2CID 13639429. doi:10.1111/j.1365-2265.1977.tb02941.x.

[pmid755846-2] [2]
Luisi M, Kicovic PM, Alicicco E, Franchi F. Effects of estradiol decanoate in ovariectomized women. J. Endocrinol. Invest. 1978, 1 (2): 101–6. PMID 755846. S2CID 38187367. doi:10.1007/BF03350355.

[Chaudhury1981-3] [3]
Ranjit Roy Chaudhury. Pharmacology of Estrogens. Elsevier Science & Technology Books. 1 January 1981: 36. ISBN 978-0-08-026869-9.

[pmid16112947-4] [4]
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2023-02-16]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始内容存档 (PDF)于2016-08-22）.

[pmid577331-5] [5]
de Visser J, van der Vies J. Oestrogenic activity of oestradiol-decanoate after oral administration to rodents. Acta Endocrinol. June 1977, 85 (2): 422–8. PMID 577331. doi:10.1530/acta.0.0850422.

[Hohl2017-6] [6]
Alexandre Hohl. Testosterone: From Basic to Clinical Aspects. Springer. 30 March 2017: 207–. ISBN 978-3-319-46086-4.

[1]

[2]

[3]

[4]

[5]

[6]